Comparison of the effects of epidermal growth factor and fetal calf serum in human endometrial carcinoma RL95-2 cells

Anticancer Research

Volumn 17, Issue 5 A, 1997, Pages 3499-3504

  Sallot, M ^a   Lascombe, I ^a   Bermont, L ^a   Jouvenot, M ^b,c  

^a Inst d'Etud de Transfert de Genes   (France)

^b UFR Sciences et Techniques   (France)

^c UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

Antisense oligodeoxynucleotides; c myc; Cancer; Cell proliferation; Endomertrium; Growth factor

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; EPIDERMAL GROWTH FACTOR;

ARTICLE; CARCINOMA CELL; CELL PROLIFERATION; FETAL CALF SERUM; HUMAN; HUMAN CELL; ONCOGENE C MYC; PRIORITY JOURNAL;

CELL DIVISION; CULTURE MEDIA; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; GROWTH INHIBITORS; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-MYC; RNA, MESSENGER; RNA, NEOPLASM; TUMOR CELLS, CULTURED;

EID: 0030731241     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Beato M: Gene regulation by steroid hormones. Cell 56: 335-344, 1989.
2. Cicatiello L, Sica V, Bresciani F and Weisz A: Identification of a specific pattern of "immediate-early" gene activation induced by estrogen during mitogenic stimulation of rat uterine cells. Receptor 3: 17-30, 1993.
3. Lin TH, Mukku VR, Verner G, Kirkland JL and Stancel GM: Autoradiographic localization of epidermal growth factor receptors to all major uterine cell types. Biol Reprod 38: 403-411, 1988.
4. Hofmann GE, Rao CV, Barrows GH, Shultz GS and Sanfilippo JS: Binding sites for epidermal growth factor in human uterine tissues and leiomyomas. J Clin Endocrinol Metab 58:880-884, 1984.
5. Lelle RJ, Talavera F, Gretz H, Roberts JA and Menon KMJ: Epidermal growth factor receptor expression in three different human endometrial cancer cell lines. Cancer 72: 519-525, 1993.
6. Cullen KJ, Yee D, Sly WS, Perdue J, Hampton B, Lippman ME and Rosen N: Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res 50: 48-53, 1990.
7. Karey KP and Sirabsku DA: Differential responsiveness of human breast cancer cell lines MCF-7 and T47 D to growth factors and 17ß-estradiol. Cancer Res 48: 4083-4092, 1988.
8. Korc M, Haussler CA and Trookman NS: Divergent effects of epidermal growth factor and transforming growth factors on a human endometrial carcinoma cell line. Cancer Res 47: 4909-4914, 1987.
9. Way DL, Grosso DS, Davis JR, Serwit EA and Christian CD: Characterization of a new human endometrial carcinoma (RL95-2) established in tissue culture. In vitro 198: 147-158, 1983.
10. Sallot M, Ordener C, Lascombe I, Propper A, Adessi GL and Jouvenot M: Differential EGF action on nuclear protooncogenes in human endometrial carcinoma RL95-2 cells. Anticancer Res 16: 401-406, 1996.
11. Evan G and Littlewood T: The role of c-myc in cell growth. Curr Spin Genet Dev 3: 44-49, 1993.
12. Askew D, Ashmun R, Simmons B and Cleveland J: Constitutive c-myc expression in IL-3 dependent myeloid cell lines suppresses cell cycle arrest and accelerates apoptosis. Oncogene 6: 1915-1922, 1991.
13. Evan G, Harrington E, Fanidi A, Land H, Amati B and Bennet M: Integrated control of cell proliferation and cell death by the c-myc oncogene. Phil Trans R Soc Lond B 345: 269-275, 1994.
14. Kimura S, Maekawa T, Hirakawa K, Murakami A and Abe T: Alterations of c-myc expression by antisense oligodeoxynucleotides enhance the induction of apoptosis in HL-60 cells. Cancer Res 55: 1379-1384, 1995.
15. Chomczynski P and Sacchi N: Single step method of RNA isolation by acid guanidium. Anal Biochem 762: 156-159, 1987.
16. Thomas PS: Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose. Proc Natl Acad Sci USA 77: 5201-5205, 1980.
17. Rigby PW, Deckmann M, Rhodes C and Berg P: Labeling desoxyribonucleic acid to high specific activity in vitro by nick-translation with DNA polymerase I. J Mol Biol 113: 237-251, 1977.
18. Sinha S, Neal GE, Legg RF, Watson JV and Pearson C: The expression of c-myc related to the proliferation and transformation of rat liver-derived epithelial cells. Br J Cancer 59: 674-676, 1989.
19. Karn J, Watson J, Lowe S, Green S and Vedeckis W: Regulation of cell cycle duration by c-myc levels. Oncogene 4: 773-787, 1989.
20. Eilers M, Schirm S and Bishop JM: The MYC protein activates transcription of the alpha-prothymosin gene EMBO J 10: 133-141, 1991.
21. Korc M, Padilla J and Grosso D: Epidermal growth factor inhibits the proliferation of a human endometrial carcinoma cell line. J Clin Endocrinol Metab 62: 874-880, 1986.
22. Zucca E and Nigg EA: Cell cycle regulation and the function of cancer genes. Annals of Oncology 6: 975-978, 1995.
23. Stein C, Subasinghe C, Shinozuka K and Cohen J: Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acid Res 16: 3209-3221, 1988.
24. Saison-Behmoaroas T, Tocque B, Rev I, Chassignol M, Thuong NT and Helene E C: Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T 24 cells proliferation. EMBO J 10: 1111-1118, 1991.
25. Crooke S: Therapeutic applications of oligonucleotides. Annu Rev Pharmacol Toxicol 32: 329-376, 1992.
26. Chavany C, Connell Y and Neckers L: Contribution of sequence and phosphorothioate content to inhibition of cell growth and adhesion caused by c-myc antisense oligomers. Mol Pharmacol 48: 738-746, 1995.
27. Guvakova MA, Yakubov LA, Vlodavsky I, Tonkinson JL and Stein CA: Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptor and remove it from low affinity binding sites on extracellular matrix. J Biol Chem 270: 2620-2627, 1995.
28. Watson PA, Pon RT and Shiu RP: Inhibition of c-myc expression by phosphorothioate antisense oligonucleotides identifies a critical role for c-myc in the growth of human breast cancer. Cancer Res 51: 3996-4000, 1991.
29. Prendergast GC and Ziff EB: A new bind for Myc. Trends Genet 8: 91-96, 1992.
30. Blackwood EM and Eisenman RN: Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA binding complex with Mvc. Science 251: 1211-1217, 1991.
31. Ayer DE, Kretzner L and Eisenman RN: Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity. Cell 72: 211-222, 1993.
32. Ayer DE, Lawrence QA and Eisenman RN: Mad-Max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3. Cell 80: 767-776, 1995.
33. Zervos AS, Gyuris J and Brent R: Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites. Cell 72: 223-232, 1993.